Franklyn G Prendergast's most recent trade in Immunome Inc was a trade of 6,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 8, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| NeuBase Therapeutics Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 37,600 | 37,600 | - | - | Stock option (right to buy) | |
| Immunome Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2021 | 3,200 | 3,200 | - | - | Stock Option (Right to Buy) | |
| NeuBase Therapeutics Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2021 | 38,135 | 38,135 | - | - | Stock option (right to buy) | |
| Immunome Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| NeuBase Therapeutics Inc | Franklyn G Prendergast | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2020 | 14,634 | 14,634 | - | - | Stock option (right to buy) |